Related Experiment Video
Updated: Jun 24, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Properties of pathogen-inactivated plasma components
1Scottish National Blood Transfusion Service, Edinburgh, United Kingdom. chris.prowse@snbts.csa.scot.nhs.uk
Abstract:
There are now 4 licensed technologies available for the pathogen inactivation of fresh frozen plasma in Europe. None of these are currently available in the United States, whereas in other geographic regions some are licensed others are not. This review addresses the different technologies available for the pathogen inactivation of plasma, their impact on the potency of the product, their efficacy in addressing microbiological contamination, as well as summarizing potential immunologic and toxicologic concerns. Published evidence of clinical efficacy is also reviewed as are various approaches to determining cost-effectiveness.
More Related Videos
Related Concept Videos
Composition of Blood Plasma
Humoral Immune Responses
Determinants of Bacterial Pathogenicity and Virulence
Vaccinations
Vaccine Production

